ArticleJNCI cancer spectrum2018
Who Will Benefit From Expanding HPV Vaccination Programs to Boys?
Article in JNCI cancer spectrum, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed, 1 synthesis or guideline pooled it, 13 citations in OpenAlex.
- Prevalence of human papillomavirus in head and neck cancer patients in India: a systematic review and meta-analysis.BMC infectious diseases · 2024Pooled it
- High Risk of New HPV Infection Acquisition Among Unvaccinated Young Men.The Journal of infectious diseases · 2024Trial
- Young Men's Communication Needs for the Human Papillomavirus (HPV) Vaccine: A Cross-Cultural, Qualitative Analysis in Scotland, Spain, and the USA.International journal of behavioral medicine · 2026Article
- European Code Against Cancer, 5th edition - cancer-causing infections and related interventions.Molecular oncology · 2026Review
- HPV Vaccine Uptake and Cervical Cancer Trends in Panama: A Reference Point for Future Impact Studies.Vaccines · 2025Article
- Health impact and cost-effectiveness of implementing gender-neutral vaccination with the 9-valent HPV vaccine in Hong Kong.Human vaccines & immunotherapeutics · 2023Article
- Gender neutral HPV vaccination programs: Reconsidering policies to expand cancer prevention globally.Frontiers in public health · 2023Review
- HPV vaccine for men: Where to? (Review).Experimental and therapeutic medicine · 2021Review
- Impact of a Gender-Neutral HPV Vaccination Program in Men Who Have Sex with Men (MSM).International journal of environmental research and public health · 2021Article
- "This Is Something Every Woman Needs. . .So Why Is It That Expensive?": Examining Privileges and Inequities in Access to a Privately Funded HPV Vaccination Program in Ghana.Global qualitative nursing researchArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Indications for human papillomavirus vaccination programs are expanding to boys. However, the rationale behind their inclusion is often not clear. Using a Bayesian synthesis framework and assuming equal vaccine coverage in both sexes, we assessed how the incremental number of cancer cases prevented and life-years gained from boys' vaccination are distributed between women, heterosexual men, and men who have sex with men (MSM). Below 60% coverage, at least 50% of the gains from boys' vaccination was attributable to cervical cancer prevention, whereas at 80% coverage, 50% of the gains was attributable to women, 15% to heterosexual men, and 35% to MSM. Above 90% coverage, 85-100% of the gains from boys' vaccination was attributable to anal and oropharyngeal cancer prevention, mainly in MSM. Sex-neutral vaccination can be advocated on grounds of bolstering herd protection to women and directly protecting men, particularly MSM, with the clinical significance of either argument determined by the coverage.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.